{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:47:41Z","timestamp":1785916061429,"version":"3.56.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873416"],"award-info":[{"award-number":["81873416"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000058"],"award-info":[{"award-number":["82000058"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070055"],"award-info":[{"award-number":["82070055"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070517"],"award-info":[{"award-number":["82070517"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019091","name":"Key Research and Development Program of Hunan Province of China","doi-asserted-by":"publisher","award":["2020SK2065"],"award-info":[{"award-number":["2020SK2065"]}],"id":[{"id":"10.13039\/501100019091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016804","name":"Natural Science Foundation of Shenzhen City","doi-asserted-by":"publisher","award":["JCYJ20190807145015194"],"award-info":[{"award-number":["JCYJ20190807145015194"]}],"id":[{"id":"10.13039\/100016804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background and aims<\/jats:title><jats:p>Proprotein convertase subtilisin\/kexin type 9 (PCSK9) has long been considered a key regulator in lipid metabolism. Its role as a potential player in immune response has recently earned much attention. However, the effects of evolocumab, an approved PCSK9 monoclonal antibody, on lipid reduction and inflammation regulation in Chinese patients with acute coronary syndrome (ACS) during their in-hospital stage after an index event are not well known.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a case-crossover pilot study (<jats:ext-link>http:\/\/www.clinicaltrials.gov\/<\/jats:ext-link>, NCT04730648) involving 31 patients hospitalized for ACS with elevated low-density lipoprotein cholesterol (LDL-C) level (\u226570 mg\/dL despite high-intensity statin) and 8 age- and gender-matched patients without coronary heart disease (CHD) as the baseline control. The patients with ACS received one dose of subcutaneous evolocumab (140 mg) on top of 10 mg\/day rosuvastatin during hospitalization. Blood samples at baseline and 72 h post-evolocumab administration were collected for lipid and cytokine assessments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The patients without CHD shared similar risk factors and LDL-C levels with the patients with ACS but exhibited a more activated inflammatory status. After single-dose in-hospital evolocumab, the median LDL-C level of patients with ACS decreased from 109.0 to 41.4 mg\/dL as early as 72 h, accompanied with reductions in other atherogenic lipids. Systemic inflammatory pattern was also altered, rendering a decrease in pro-inflammatory and anti-inflammatory cytokines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this case-crossover study of the effect of PCSK9 antibody among Chinese patients, evolocumab on top of high-intensity statin during hospitalization led to a remarkable and rapid reduction in atherogenic lipids and an alteration in inflammatory status at early-stage post-ACS.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.939791","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T05:40:45Z","timestamp":1660023645000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: A pilot study on Chinese patients"],"prefix":"10.3389","volume":"9","author":[{"given":"Ziwei","family":"Ou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaixin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benhui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinli","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tangzhiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e1046","DOI":"10.1161\/CIR.0000000000000699","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation."},{"key":"B2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.15829\/1560-4071-2020-3826","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jacl.2020.01.004","article-title":"Residual risk for coronary heart disease events and mortality despite intensive medical management after myocardial infarction","volume":"14","author":"Brown","year":"2020","journal-title":"J Clin Lipidol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3389\/fcvm.2020.00088","article-title":"The evolving understanding and approach to residual cardiovascular risk management","volume":"7","author":"Dhindsa","year":"2020","journal-title":"Front Cardiovasc Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1161\/STROKEAHA.117.018140","article-title":"Effects of statin intensity and adherence on the long-term prognosis after acute ischemic stroke","volume":"48","author":"Kim","year":"2017","journal-title":"Stroke."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e011200","DOI":"10.1136\/heartasia-2019-011200","article-title":"Clinical consequences of poor adherence to lipid-lowering therapy in patients with cardiovascular disease: can we do better?","volume":"11","author":"Klimis","year":"2019","journal-title":"Heart Asia."},{"key":"B7","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jacc.2016.06.006","article-title":"Searching for adherence: can we fulfill the promise of evidence-based medicines?","volume":"68","author":"Armstrong","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e005041","DOI":"10.1161\/CIRCOUTCOMES.118.005041","article-title":"Medication discontinuation in the IMPROVE-IT TRIAL","volume":"12","author":"Navar","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","article-title":"PCSK9: from basic science discoveries to clinical trials","volume":"122","author":"Shapiro","year":"2018","journal-title":"Circ Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/biof.1619","article-title":"Beyond cholesterol metabolism: the pleiotropic effects of proprotein convertase subtilisin\/kexin type 9 (PCSK9)","volume":"46","author":"Cesaro","year":"2020","journal-title":"Genet Mutat Exp Perspect Long-term Inhibit Biofact."},{"key":"B11","doi-asserted-by":"publisher","first-page":"19180","DOI":"10.1002\/jcp.28612","article-title":"The immune functions of PCSK9: Local and systemic perspectives","volume":"234","author":"Liu","year":"2019","journal-title":"J Cell Physiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"639727","DOI":"10.3389\/fcvm.2021.639727","article-title":"PCSK9 functions in atherosclerosis are not limited to plasmatic LDL-cholesterol regulation","volume":"8","author":"Luquero","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS)","volume":"74","author":"Koskinas","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1161\/CIRCULATIONAHA.120.046320","article-title":"Effect of evolocumab on atherogenic lipoproteins during the peri- and early postinfarction period: a placebo-controlled, randomized trial","volume":"142","author":"Leucker","year":"2020","journal-title":"Circulation."},{"key":"B19","unstructured":"Acute coronary syndrome: presentation and diagnostic evaluation119\n            BarstowC\n          32150364FP Essent.4902020"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.jacc.2019.07.061","article-title":"From focal lipid storage to systemic inflammation: JACC review topic of the week","volume":"74","author":"Libby","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/eurheartj\/ehaa099","article-title":"Targeting cardiovascular inflammation: next steps in clinical translation","volume":"42","author":"Lawler","year":"2021","journal-title":"Eur Heart J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1016\/j.jacc.2018.09.052","article-title":"Medical therapy for long-term prevention of atherothrombosis following an acute coronary syndrome: JACC state-of-the-art review","volume":"72","author":"Gallone","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur Heart J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.amjcard.2017.02.020","article-title":"Effects of RG7652, a monoclonal antibody against PCSK9, on LDL-C, LDL-C subfractions, and inflammatory biomarkers in patients at high risk of or with established coronary heart disease (from the phase 2 EQUATOR study)","volume":"119","author":"Baruch","year":"2017","journal-title":"Am J Cardiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1161\/CIRCRESAHA.116.304794","article-title":"Identification of a non-growth factor role for GM-CSF in advanced atherosclerosis: promotion of macrophage apoptosis and plaque necrosis through IL-23 signaling","volume":"116","author":"Subramanian","year":"2015","journal-title":"Circ Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/jcb.24941","article-title":"VEGF and angiopoietins promote inflammatory cell recruitment and mature blood vessel formation in murine sponge\/Matrigel model","volume":"116","author":"Sinnathamby","year":"2015","journal-title":"J Cell Biochem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nrd1901","article-title":"Anti-inflammatory effects of statins: clinical evidence and basic mechanisms","volume":"4","author":"Jain","year":"2005","journal-title":"Nat Rev Drug Discov."},{"key":"B33","doi-asserted-by":"publisher","first-page":"105735","DOI":"10.1016\/j.biocel.2020.105735","article-title":"Statins reduce vascular inflammation in atherogenesis: a review of underlying molecular mechanisms","volume":"122","author":"Liberale","year":"2020","journal-title":"Int J Biochem Cell Biol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.939791\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T05:40:51Z","timestamp":1660023651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.939791\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":33,"alternative-id":["10.3389\/fcvm.2022.939791"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.939791","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,9]]},"article-number":"939791"}}